NuCana plc American Depositary Share (NCNA) Stock Price
NCNAStock
$0.99−80.74%52W
Market Cap$4.12M
P/E—
PEG Ratio—
Div yield—
Beta2.45
NCNA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-64.07%
Price vs S&P 500 (4W)-23.67%
VGM Score30.09
NCNA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q4 2024 | -$586.43 | -$86.43 | +85.26%(+$500.00) | |
| Q3 2024 | -$1052.90 | -$585.89 | +44.35%(+$467.01) | |
| Q2 2024 | -$1063.57 | -$1028.65 | +3.28%(+$34.92) | |
| Q1 2024 | -$1092.89 | -$1097.69 | -0.44%(-$4.80) |
NCNA Analyst Recommendations
Mar 2025
Apr 2025
May 2025
Jun 2025
4.00
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
NCNANuCana plc American Depositary Share | — | — | D | — | — | — | — | $0.99 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About NuCana plc American Depositary Share
NuCana PLC is a biopharmaceutical company developing cancer treatments based on its proprietary ProTide technology, which delivers higher concentrations of anti-cancer metabolites to tumor cells to overcome drug resistance. The company's pipeline comprises three candidates—NUC-3373, NUC-7738, and Acelarin—with primary operations in the United States.